Muraglitazar (CAS 331741-94-7)

Muraglitazar (CAS 331741-94-7) References

1. Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.  |  Devasthale, PV., et al. 2005. J Med Chem. 48: 2248-50. PMID: 15771468
2. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.  |  Harrity, T., et al. 2006. Diabetes. 55: 240-8. PMID: 16380499
3. Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites.  |  Li, W., et al. 2006. Drug Metab Dispos. 34: 807-20. PMID: 16467134
4. Assessment of dose proportionality of muraglitazar after repeated oral dosing in rats via a sparse sampling methodology.  |  Yao, M., et al. 2007. Biopharm Drug Dispos. 28: 35-42. PMID: 17117455
5. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.  |  Hosagrahara, VP., et al. 2006. Xenobiotica. 36: 1227-38. PMID: 17162469
6. Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?  |  Mittra, S., et al. 2007. Br J Pharmacol. 150: 480-7. PMID: 17211457
7. The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice.  |  Tozzo, E., et al. 2007. J Pharmacol Exp Ther. 321: 107-15. PMID: 17259449
8. Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.  |  Tannehill-Gregg, SH., et al. 2007. Toxicol Sci. 98: 258-70. PMID: 17426106
9. Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.  |  Waites, CR., et al. 2007. Toxicol Sci. 100: 248-58. PMID: 17675651
10. Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.  |  Suh, YG., et al. 2008. J Med Chem. 51: 6318-33. PMID: 18826205
11. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat.  |  Suzuki, S., et al. 2010. Toxicol Sci. 113: 349-57. PMID: 19858066
12. Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment.  |  Zhang, D., et al. 2011. Drug Metab Dispos. 39: 123-31. PMID: 20876787
13. The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.  |  Pruimboom-Brees, IM., et al. 2012. Toxicol Pathol. 40: 810-8. PMID: 22504321
14. Anti-inflammatory properties of a dual PPARgamma/alpha agonist muraglitazar in in vitro and in vivo models.  |  Paukkeri, EL., et al. 2013. Arthritis Res Ther. 15: R51. PMID: 23594962